Pregnan-20-one, 3,17-dihydroxy- | 40248-23-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Pregnan-20-one, 3,17-dihydroxy-
• 英文别名: 1-[(8R,9S,10S,13S,14S,17R)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
• CAS: 40248-23-5
• 化学式: C₂₁H₃₄O₃
• 分子量: 334.5
• InChiKey: LKQDFQLSEHWIRK-JAMIXBCGSA-N

物化性质

• 沸点：
  465.4±20.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• TREATMENT OF TUMOURS
  申请人：Hagstrom Tomas

  公开号：US20070111973A1

  公开（公告）日：2007-05-17

  The present invention refers to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wut-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are -5-androstene-17-ol, androstane-17-ol-pregnane-17-ol or pregnane-17-ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3B,17-dio 1 or androstane-3B-diol, an enzyme and a sulfotransferase to provide 5-androstene-17-ol-3B-sulfate or corresponding andros tane derivative (17-AEDS or 17-AADS); and mixing the 17-AEDS or 17-AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to peroxisome proliferators-activated receptor—(PPAR) is produced.

  本发明涉及类固醇衍生物用作药物。更具体地，本发明还涉及在制造用于治疗良性和/或恶性肿瘤的药物中使用5-雄烯烷，5-孕酮或相应饱和衍生物（雄烷或孕烷）的类固醇衍生物，该药物能够中断Wut信号传导的紊乱，例如在G1期细胞周期停滞，并/或提供血管生成抑制作用。此类类固醇衍生物的例子是-5-雄烯烷-17-醇，雄烷-17-醇-孕烷-17-醇或孕烷-17-醇衍生物。此外，本发明还涉及一种用于制备用于治疗良性和/或恶性肿瘤和/或炎症症状的药物的方法，包括以下步骤：接触5-雄烷-3B，17-二酮或雄烷-3B-二醇，一种酶和一种硫酸转移酶，以提供5-雄烯烷-17-醇-3B-硫酸酯或相应的雄烷衍生物（17-AEDS或17-AADS）;并将所生产的17-AEDS或17-AADS与适当的载体混合；从而制备出能够作为过氧化物酶体增殖物激活受体-（PPAR）配体的药物。
• Methods to rebalance the hypothalamic-pituitary-gonadal axis
  申请人：JangoBio, LLC

  公开号：US11253549B2

  公开（公告）日：2022-02-22

  A hypothalamic-pituitary-gonadal (HPG) axis of a patient in need thereof is rebalanced by administering a therapeutically effective amount of at least one donor cell.

  通过施用治疗有效量的至少一种供体细胞，重新平衡有需要的患者的下丘脑-垂体-性腺轴（HPG）。
• ASSAY FOR DETECTION OF ADRENAL TUMOUR
  申请人：The University of Birmingham

  公开号：EP2396658B1

  公开（公告）日：2015-12-16
• Use of pregnane steroid derivatives for enhancing physical performance
  申请人：Marchewitz Eric

  公开号：US20060211667A1

  公开（公告）日：2006-09-21

  A method of increasing lean body mass in humans comprises administering a pregnane steroid derivative or a physiologically acceptable salt or ester thereof of the general formula: wherein R1=H and R2=H, or R1 and R2 combined form a single bond; R3 is one of OH and O; R5 is one of an α-hydrogen and a β-hydrogen; R6 is one of α-methyl and H; R7 is one of α-methyl and H; R17 is one of H and OH; and R20 is one of OH and O.
• Use of hydroxypregnenolone derivatives for enhancing health and physical performance
  申请人：Marchewitz Eric D.

  公开号：US20130281418A1

  公开（公告）日：2013-10-24

  A method for the use of derivatives of hydroxypregnenolone (3-beta,17-alpha-dihydroxypregn-5-en-3-one) to enhance health and physical performance in humans and more particularly to the use of hydroxypregnenolone derivatives for restoring renal hormonal balance, decreasing body weight, reducing adipose tissue, increasing endurance, promoting skeletal muscle growth, boosting androgen levels, inhibiting aromatase, and increasing cognitive function.